Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. (TELO) priced its initial public offering on Feb 12, 2024 at $7.00 per share, raising $7M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $207.3M. Kingswood was lead-left underwriter. Foley & Lardner advised the company and Lucosky Brookman advised the underwriters.

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company developing TELOMIR-1, an oral small molecule intended to act as a metal enzyme inhibitor of essential metals such as zinc and copper, targeting age-related inflammatory conditions.

Status

IPO

Ticker

TELO

Exchange

Nasdaq Capital Market

Priced

Feb 12, 2024

IPO price

$7.00

Raised

$7M

Market cap at IPO price

$207.3M

First filed

Nov 14, 2023

Underwriters

Kingswood

Company counsel

Foley & Lardner

Underwriters' counsel

Lucosky Brookman

Sector

Biotech & pharma

Country / state

FL

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.